1. Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
   Pauline Rottier et al, 2023, Frontiers in Oncology CrossRef
2. Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
   Wei Wang et al, 2023, Technology in Cancer Research & Treatment CrossRef
3. Pediatric brain tumor patients display altered immune activation and reduced lymphopoiesis at the onset of disease
   Marco Rosichini et al, 2024, npj Precision Oncology CrossRef
4. The prognostic value of absolute lymphocyte count and neutrophil‐to‐lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta‐analysis
   Bulin Sang et al, 2024, Frontiers in Oncology CrossRef
5. Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies
   Hui-Chen Su et al, 2024, Targeted Oncology CrossRef
6. Effect of Radiation Therapy on Composition of Lymphocyte Populations in Patients with Primary Breast Cancer
   Irina Kobzeva et al, 2023, Journal of Personalized Medicine CrossRef
7. Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
   Takayuki Kobayashi et al, 2024, BMC Cancer CrossRef
8. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
   Alberto D’Angelo et al, 2022, Current Issues in Molecular Biology CrossRef
9. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
   Wei Wang et al, 2024, BMC Cancer CrossRef
10. Systemic Inflammatory Response as a Prognostic Factor in Breast Cancer. Part II. Hematological Markers of Inflammation
    Natalia S. Sergeeva et al, 2023, Annals of the Russian academy of medical sciences CrossRef